Gonzalo Rodríguez Martínez

Gonzalo Rodríguez Martínez

Auto-generated profile, based on publicly available information

Gonzalo Rodríguez Martínez

Restorative Dentistry Department, Faculty of Dentistry, Dental School, University of Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2026 in Clinical Oral Investigations
Verified
Journal Article
Closed access
PDF file
GRGonzalo Rodriguez
Gonzalo Rodriguez
EFEduardo Fernandez
Eduardo Fernandez
Alain Manuel Chaple-GilAlain Manuel Chaple-Gil
Alain Manuel Chaple-Gil
RCRafael Ignacio Contador-Cotroneo
Rafael Ignacio Contador-Cotroneo
CMCristian Bersezio Miranda
Cristian Bersezio Miranda
RCRodrigo Cabello
Rodrigo Cabello

15 December 2025 in European Journal of Oral Sciences
Verified
Journal Article
Closed access
RIRodrigo Cabello Ibacache
Rodrigo Cabello Ibacache
SFSimone Faleiros
Simone Faleiros
MDMario Diaz- Dosque
Mario Diaz- Dosque
BRBegoña Ruiz
Begoña Ruiz
RCRafael Ignacio Contador-Cotroneo
Rafael Ignacio Contador-Cotroneo
GMGonzalo Rodríguez Martínez
Gonzalo Rodríguez Martínez

1 January 2026 in Pain Research and Management
Verified
Journal Article
Open access
JCJoatan Lucas De Sousa Gomes Costa
Joatan Lucas De Sousa Gomes Costa
LALeonardo Díaz Agurto
Leonardo Díaz Agurto
Alain Manuel Chaple-GilAlain Manuel Chaple-Gil
Alain Manuel Chaple-Gil
GMGonzalo Rodríguez Martínez
Gonzalo Rodríguez Martínez
RIRodrigo Cabello Ibacache
Rodrigo Cabello Ibacache
Milton Carlos KugaMilton Carlos Kuga
Milton Carlos Kuga
Background: Oral mucositis (OM) is a debilitating complication of cancer therapy, particularly in head and neck cancer patients, with significant adverse effects on quality of life (QoL). Although numerous interventions have been investigated, their impact on QoL remains inconsistently reported and poorly synthesized. Methods: An umbrella review was conducted following PRISMA 2020 and Joanna Briggs Institute (JBI) guidelines. Five databases (PubMed, Embase, Scopus, Web of Science, and Cochrane Library) were searched from inception to March 2024. Reviews were eligible if they evaluated any therapeutic intervention for OM and reported QoL‐related outcomes using validated tools. Methodological quality was appraised using AMSTAR 2, and findings were narratively synthesized and thematically categorized. The protocol was registered in PROSPERO (CRD420251044088). Results: Eight systematic reviews (257 primary studies) met the inclusion criteria. Photobiomodulation, honey, black mulberry, and botanical agents such as SAMITAL showed consistent improvement in QoL domains, including pain relief, oral function, and emotional well‐being. Gabapentin demonstrated potential in reducing opioid use and early mucositis‐related pain, though findings were mixed across trials. QoL was most commonly assessed using the EORTC QLQ‐C30, FACT‐HN, and UW‐QOL. Overall, heterogeneity in intervention protocols and QoL instruments limited comparability. Conclusions: This review highlights the most promising interventions for improving QoL in patients with OM. Standardizing QoL measurement and prioritizing patient‐reported outcomes in future trials is essential to inform evidence‐based supportive oncology care.